Abstract
Neurodegenerative diseases, like Alzheimer´s and Parkinson´s disease, are a group of disorders that have in common their increasingly high prevalence along with the shortage of effective treatments. In addition, the scientific community faces the challenge of getting the drugs used in these treatments to cross the blood-brain barrier (BBB) and reach the brain in sufficient concentration to be able to exert its effect. Hence, researchers across multiple disciplines are working together in order to improve the ability of therapeutics to penetrate the BBB. In this sense, the use of nanomedicine, nanoscale structures for drug delivery, exhibits a really high therapeutic potential in the field of neurodegenerative diseases therapy.
Since there is new evidence that neuroinflammation produced by reactive microglia contributes to the activation and pathogenesis of neurological disorders, many investigations focus on the identification of new targets whose inhibition can reduce, totally or partially, microglial activation. This review analyzes a wide variety of compounds as possible candidates to achieve this target, from compounds with a natural origin to anti-diabetics, antidepressants, antibiotics and hormones. We also discuss the different strategies to enhance the capacity of these compounds to cross the BBB. Although this review focuses on PLGA nanoparticles as one of the most versatile drug delivery nanosystems, we also describe other strategies, such as direct intranasal administration (nose-tobrain), novel viral vectors and novel implanted catheters.
Keywords: Alzheimer´s disease, anti-inflammatory drugs, nanoparticles, neuroinflammation, nose-to-brain, Parkinson´s disease, PLGA.
Current Pharmaceutical Design
Title:Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases
Volume: 24 Issue: 14
Author(s): Maria Dolores Cayero-Otero, Ana M. Espinosa-Oliva*, Antonio J. Herrera, Irene Garcia-Dominguez, Mercedes Fernandez-Arevalo, Lucia Martin-Banderas and Rocio M. de Pablos
Affiliation:
- Departamento de Bioquimica y Biologia Molecular, Facultad de Farmacia, Universidad de Sevilla, and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla,Spain
Keywords: Alzheimer´s disease, anti-inflammatory drugs, nanoparticles, neuroinflammation, nose-to-brain, Parkinson´s disease, PLGA.
Abstract: Neurodegenerative diseases, like Alzheimer´s and Parkinson´s disease, are a group of disorders that have in common their increasingly high prevalence along with the shortage of effective treatments. In addition, the scientific community faces the challenge of getting the drugs used in these treatments to cross the blood-brain barrier (BBB) and reach the brain in sufficient concentration to be able to exert its effect. Hence, researchers across multiple disciplines are working together in order to improve the ability of therapeutics to penetrate the BBB. In this sense, the use of nanomedicine, nanoscale structures for drug delivery, exhibits a really high therapeutic potential in the field of neurodegenerative diseases therapy.
Since there is new evidence that neuroinflammation produced by reactive microglia contributes to the activation and pathogenesis of neurological disorders, many investigations focus on the identification of new targets whose inhibition can reduce, totally or partially, microglial activation. This review analyzes a wide variety of compounds as possible candidates to achieve this target, from compounds with a natural origin to anti-diabetics, antidepressants, antibiotics and hormones. We also discuss the different strategies to enhance the capacity of these compounds to cross the BBB. Although this review focuses on PLGA nanoparticles as one of the most versatile drug delivery nanosystems, we also describe other strategies, such as direct intranasal administration (nose-tobrain), novel viral vectors and novel implanted catheters.
Export Options
About this article
Cite this article as:
Cayero-Otero Dolores Maria , Espinosa-Oliva M. Ana *, Herrera J. Antonio , Garcia-Dominguez Irene , Fernandez-Arevalo Mercedes, Martin-Banderas Lucia and de Pablos M. Rocio , Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases, Current Pharmaceutical Design 2018; 24 (14) . https://dx.doi.org/10.2174/1381612824666180403113015
DOI https://dx.doi.org/10.2174/1381612824666180403113015 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antimicrobial Action of Chelating Agents: Repercussions on the Microorganism Development, Virulence and Pathogenesis
Current Medicinal Chemistry Opioids in Neuropathic Pain
Current Pharmaceutical Design Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature
Reviews on Recent Clinical Trials Purification and Partial Characterization of a Lectin from Canavalia Grandiflora Benth. Seeds
Protein & Peptide Letters Roles of Adrenomedullin in Hypertension and Hypertensive Organ Damage
Current Hypertension Reviews Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton’s Jelly Cells
Recent Patents on Regenerative Medicine Modulation of Arachidonic Acid Metabolism in Niemann-Pick Disease Type C Cells
Current Psychopharmacology Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients
CNS & Neurological Disorders - Drug Targets Role of Nitric Oxide in Neurodegeneration: Function, Regulation, and Inhibition
Current Neuropharmacology Neuroendocrine Stimulation of Mucosal Immune Cells in Inflammatory Bowel Disease
Current Pharmaceutical Design Homocysteine, Cardiovascular Inflammation, and Myocardial Remodeling
Cardiovascular & Hematological Disorders-Drug Targets 5-HT1A Receptor, an Old Target for New Therapeutic Agents
Current Topics in Medicinal Chemistry Editorial (Hot Topic: New Advances of Drug Design in Alzheimer's Disease)
Current Bioactive Compounds Protein Interactions Between the C-Terminus of Aβ-Peptide and Phospholipase A<sub>2</sub> - A Structure Biology Based Approach to Identify Novel Alzheimer's Therapeutics
CNS & Neurological Disorders - Drug Targets Erythropoietin Employs Cell Longevity Pathways of SIRT1 to Foster Endothelial Vascular Integrity During Oxidant Stress
Current Neurovascular Research Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link?
Current Neuropharmacology Editorial (Thematic Issue: Perspectives and Challenges in Rational Exploitation of Phytochemicals in Cure, Control and Management of Diseases)
Current Pharmaceutical Design Mitochondrial Membrane Lipids in Life and Death and their Molecular Modulation by Diet: Tuning the Furnace
Current Drug Targets Acknowledgements to Reviewers:
Current Alzheimer Research